Risk factors
Tango Therapeutics (TNGX) risk factors
Item 1A of every Tango Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors78 risks7 new8 dropped15 reworded
New disclosures highlight risks from the Inflation Reduction Act on small molecule drug pricing and Unified Patent Court challenges in Europe. Additional focus centers on AI tool integration risks, third-party biomarker development, combination therapies like vopimetostat with RevMed inhibitors, and reliance on CROs for clinical trials.
Filed Mar 05, 2026 - FY2024 10-K risk factors79 risks
Precision oncology company facing significant net losses, an accumulated deficit, and lacking commercial products.
Filed Feb 27, 2025